IONIS PHARMACEUTICALS INC
bepirovirsen
chronic hepatitis B
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for bepirovirsen in chronic hepatitis B are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Planned regulatory submissions to health authorities worldwide in 2026 based on positive topline results from pivotal Phase 3 B-Well 1 and B-Well 2 studies, in which bepirovirsen demonstrated a statistically significant and clinically meani”